Pregabalin (All indications) updated on 04-22-2025

Low birth weight (< 2500g)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S16068
R66681		 Christensen (All indications) (Controls exposed to LTG), 2024 Low birth weight (<2500 g) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.39 [1.13;1.69] C
excluded (control group) 		136/2,214   395/8,756 531 2,214
ref
S16025
R66520		 Christensen (All indications) (Controls unexposed, general population), 2024 Low birth weight (<2500 g) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 1.23 [1.03;1.47] 136/2,214   141,442/4,467,848 141,578 2,214
ref
S17225
R72132		 Kaskal (Indications NOS), 2024 Low birth weight (<2500 g) during pregnancy (anytime or not specified) cohort unexposed (general population or NOS) Adjustment: No 4.34 [1.20;15.65] 6/27   5/81 11 27
ref
S10100
R36795		 Coste (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 Weight at birth <2500 g during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No 1.20 [0.94;1.52] C
excluded (control group) 		118/1,627   179/2,916 297 1,627
ref
S8541
R28339		 Coste (Controls unexposed, NOS) (Mixed indications), 2020 Weight at birth <2500 g during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 1.38 [1.15;1.67] C 118/1,627   91,455/1,710,441 91,573 1,627
ref
Total 3 studies 1.35 [1.08;1.69] 233,162 3,868
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Christensen (All indications) (Controls unexposed, general population), 2024Christensen, 2024 1 1.23[1.03; 1.47]141,5782,21449%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Kaskal (Indications NOS), 2024Kaskal, 2024 2 4.34[1.20; 15.65]11273%ROB confusion: criticalROB selection: unclearROB classification: unclearROB missing: unclearROB mesure: unclearROB reporting: moderate Coste (Controls unexposed, NOS) (Mixed indications), 2020Coste, 2020 3 1.38[1.15; 1.67]91,5731,62748%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 52% 1.35[1.08; 1.69]233,1623,8680.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: All indications) (Controls unexposed, general population; 2: Indications NOS; 3: Controls unexposed, NOS) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.35[1.08; 1.69]233,1623,86852%NAChristensen (All indications) (Controls unexposed, general population), 2024 Kaskal (Indications NOS), 2024 Coste (Controls unexposed, NOS) (Mixed indications), 2020 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.35[1.08; 1.69]233,1623,86852%NAChristensen (All indications) (Controls unexposed, general population), 2024 Kaskal (Indications NOS), 2024 Coste (Controls unexposed, NOS) (Mixed indications), 2020 3 Tags Adjustment   - No  - No 2.04[0.71; 5.89]91,5841,65466%NAKaskal (Indications NOS), 2024 Coste (Controls unexposed, NOS) (Mixed indications), 2020 2   - Yes  - Yes 1.23[1.03; 1.47]141,5782,214 -NAChristensen (All indications) (Controls unexposed, general population), 2024 1 All studiesAll studies 1.35[1.08; 1.69]233,1623,86852%NAChristensen (All indications) (Controls unexposed, general population), 2024 Kaskal (Indications NOS), 2024 Coste (Controls unexposed, NOS) (Mixed indications), 2020 30.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 10100, 16068

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.35[1.08; 1.69]233,1623,86852%NAChristensen (All indications) (Controls unexposed, general population), 2024 Kaskal (Indications NOS), 2024 Coste (Controls unexposed, NOS) (Mixed indications), 2020 3 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.30[1.12; 1.52]8283,8410%NAChristensen (All indications) (Controls exposed to LTG), 2024 Coste (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 20.510.01.0